Dog Immune-Mediated Haemolytic Anaemia (IMHA)

Immune-mediated haemolytic anaemia (IMHA) is a serious, potentially life-threatening condition in dogs where the immune system mistakenly attacks and destroys its own red blood cells. Early recognition and treatment are critical for survival.

Key Facts

IMHA is the most common cause of severe anaemia in dogs; it occurs when autoantibodies coat red blood cells, triggering their destruction by the immune system
The condition can be primary (idiopathic, no known cause) or secondary to infection, drugs, toxins, cancer, or bee stings
Breeds with higher predisposition include American Cocker Spaniels, English Springer Spaniels, Old English Sheepdogs, and Poodles
Clinical signs include extreme lethargy, pale or yellow-tinged gums, rapid breathing, weakness, collapse, and dark brown or red urine
Diagnosis involves blood tests showing low packed cell volume (PCV), positive Coombs test, spherocytes on blood smear, and signs of regenerative anaemia
IMHA carries a mortality rate of approximately 20–70% even with treatment, partly due to concurrent thromboembolic complications — clot formation is a major cause of death
Treatment includes immunosuppressive drugs (prednisolone ± azathioprine, mycophenolate, or ciclosporin) and often blood transfusions
Relapses are common — around 20–30% of dogs that survive the initial episode will relapse, sometimes months or years later

Welfare Considerations

IMHA causes profound suffering through severe fatigue, weakness, breathlessness, and the distress of hospital confinement and repeated blood sampling. The risk of painful thromboembolism — where clots block blood vessels — adds another serious welfare concern. Dogs with IMHA often require intensive care hospitalisation for days or weeks, which is inherently stressful. Long-term immunosuppressive medication causes its own side effects including increased thirst, urination, appetite changes, and susceptibility to infection. The uncertainty of prognosis and the high relapse rate means families face repeated crises. Good palliative care, minimising handling stress, careful vascular monitoring, and honest prognosis discussions with owners are all essential components of compassionate IMHA management.

What You Can Do

Know the warning signs: pale or yellow gums, sudden extreme weakness, and rapid breathing in your dog require emergency vet assessment
If diagnosed, follow immunosuppressive protocols carefully and never stop medication abruptly without veterinary guidance
Ask your vet about thromboprophylaxis — antiplatelet or anticoagulant medication to reduce clot risk
Support research into IMHA treatments through veterinary research organisations
Consider pet insurance, as IMHA treatment can cost thousands of pounds or dollars in intensive care